大黄蜇虫丸治疗慢性肝炎肝纤维化的临床疗效观察  

Clinical Efficacy of Dahuang Zhechong Pill on Chronic Hepatitis with Hepatic Fibrosis

作　　者：李文琍 吴诗品 

机构地区：[1]暨南大学第二附属医院深圳市人民医院感染内科,深圳市518020

出　　处：《中国药房》2008年第21期1658-1660,共3页China Pharmacy

摘　　要：目的:观察大黄蜇虫丸治疗慢性肝炎肝纤维化的临床疗效。方法:选择128例慢性肝炎肝纤维化患者,随机分为治疗组68例和对照组60例。2组患者均予以常规护肝治疗,治疗组加用大黄蜇虫丸(6g.d-1)。疗程均为6个月。观察2组治疗后症状、体征、肝功能及血清玻璃酸(HA)、Ⅲ型前胶原肽(PCⅢ)、甘氨胆酸(CG)、Ⅳ型胶原(ⅣC)、B超影像等改变情况。结果:治疗组HA、PCⅢ、CG、ⅣC均有明显下降,2组比较有显著性差异(P<0.05)。治疗组临床症状明显改善,血清丙氨酸氨基转移酶、门冬氨酸氨基转移酶等指标均显著降低。结论:大黄蜇虫丸能减轻患者症状、改善肝功能和肝纤维化,是治疗慢性肝炎肝纤维化的有效药物之一。OBJECTIVE ： To evaluate the clinical effect of Dahuang zhechong pill on chronic hepatitis with hepatic fibrosis. METHODS： A total of 128 patients with chronic hepatitis with hepatic fibrosis were randomly divided into treatment group（68 cases） and control group（ 60 cases）. The control group received routine hepatic protective therapy, while the treatment group received routine hepatic protective therapy and Dahuang zhechong pills（6 g · d^-1） concomitantly. The course of treatment lasted for 6 months. The clinical symptoms, liver function, hyaluronic acid（HA）, pro - collagen Ⅲ （PC Ⅲ ） ,cholyglycine （CG） and collagen type Ⅳ （ ⅣC）, and ultrasound image were observed in both groups. RESULTS： Levels of serum HA, PC Ⅲ ,CG, and ⅣC decreased significantly in treatment group, and the difference between two groups was significant（P〈0.05）.And in the treatment group, the clinical symptoms improved significantly, and the indexes ALT and AST etc decreased significantly as well. CONCLUSION： Dahuang zhechong pill was an effective drug for chronic hepatitis with hepatic fibrosis in that it can alleviate the symptom of hepatic fibrosis and improve the hepatic function.

关 键 词：慢性肝炎 肝纤维化 大黄蜇虫丸 临床疗效 

分 类 号：R283.64[医药卫生—中药学]